Gilead Sciences has announced the completion of the previously announced transaction for Dodgers Merger Sub a wholly-owned subsidiary of Gilead (purchaser), to acquire Kite Pharma, for $180 per share, net to the seller in cash, without interest, or approximately $11.9bn in the aggregate.
Endocyte has announced the completion of an exclusive worldwide license of PSMA-617 from ABX GmbH.
The US Department of Health & Human Services (HHS) has accelerated the development of first Ebola vaccines and drugs.
Novartis has joined forces with researchers from the University of California, Berkeley, to develop new technologies for the discovery of next-generation therapeutics, pursuing the vast number of disease targets in cancer and other illnesses that have eluded traditional small-molecule compounds and are considered undruggable.
Autolus, a clinical-stage biopharmaceutical company focused on the development and commercialisation of next-generation engineered T-cell therapies, announced that it closed on a $80m (£59m) series C financing.
Landos Biopharma, an emerging biopharmaceutical company focused on developing improved treatments for autoimmune diseases, announced that it has raised $10m in a series A financing led by life sciences investment management firm Perceptive Advisors, which will serve as its exclusive investor for the Series A round.
MilliporeSigma announced the opening of its first BioReliance end-to-end biodevelopment center in the Asia Pacific (APAC) region.
Labcyte announced that GSK has joined its consortium with AstraZeneca to combine acoustic liquid dispensing technology from Labcyte with Mass Spectrometry (MS) for use in high throughput small molecule screening and other drug discovery applications.
Ultragenyx Pharmaceutical has made a proposal to acquire all of the outstanding shares of common stock of Dimension Therapeutics for $5.50 per share, or approximately $138m, in cash at close to be effectuated via a tender offer.
Mustang Bio, a Fortress Biotech company, has announced the expansion of its pipeline of CAR T therapies into CD20-directed immunotherapies.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.